MiR-140-3p is Involved in In-Stent Restenosis by Targeting C-Myb and BCL-2 in Peripheral Artery Disease

Journal of Atherosclerosis and Thrombosis
Zhengrong ZhuShen-ming Wang

Abstract

In-Stent Restenosis (ISR) is the major reason for recurrent ischemia and amputation after endovascular treatment of Peripheral Artery Disease (PAD). Our previous study demonstrated that miR-140-3p is significantly down-regulated in PAD arteries. However, expression and function of miR-140-3p in ISR of human PAD are currently unclear.The aim of this study is to determine the miR-140-3p expression and its regulative role in ISR of PAD. The RNA level was determined by quantitative real-time polymerase chain Reaction (qRT-PCR) and in situ hybridization. Primary cultured ASMCs were isolated from human femoral arterial of the healthy donors or ISR patients. Cell proliferation was determined by Edu incorporation and CCK-8 assay. Apoptosis was determined by Annexin-Ⅴ/PI Double-Staining assay and TUNEL assay. A rat carotid artery balloon angioplasty model was used to investigate the effect of miR-140-3p on restenosis. MiR-140-3p was significantly down-regulated in PAD and ISR arteries than normal arteries. Primary cultured ISR ASMCs exhibited elevated proliferation and down-regulated miR-140-3p than normal ASMCs. Transfection of miR-140-3p mimic attenuated PDGF-BB-induced proliferation in cultured ASMCs and induced apoptosis. Luciferase...Continue Reading

References

Feb 22, 2002·The Journal of Pathology·A SaxenaD J Thomson
Apr 24, 2004·Science·Soraya YektaDavid P Bartel
Sep 17, 2004·Nature·Victor Ambros
Sep 5, 2006·Apoptosis : an International Journal on Programmed Cell Death·Ozgur Kutuk, Huveyda Basaga
Jan 16, 2007·Journal of Vascular Surgery·L NorgrenUNKNOWN TASC II Working Group
Jun 22, 2007·Vascular Health and Risk Management·Nicolas W Shammas
Mar 12, 2010·New Biotechnology·Takaya Saito, Pal Saetrom
Dec 22, 2010·Expert Review of Molecular Diagnostics·Md Saha JamaluddinChangyi Chen
Feb 24, 2011·Current Molecular Medicine·T M WitkosW J Krzyzosiak
Aug 16, 2011·Journal of cardiology·Gaku Nakazawa
Aug 26, 2011·Vascular Pharmacology·Manuela QuintavalleLeonardo Elia
May 23, 2012·Nature Reviews. Cardiology·Fumiyuki OtsukaRenu Virmani
Oct 1, 2013·Atherosclerosis·Andrea BorghiniMaria Grazia Andreassi
May 30, 2015·Journal of the American College of Cardiology·Robert A McDonaldAndrew H Baker
May 30, 2015·Journal of the American College of Cardiology·Gary L Schaer, Chunxiang Zhang
Jul 18, 2015·Arteriosclerosis, Thrombosis, and Vascular Biology·Dong WangLars Maegdefessel
Sep 16, 2015·Journal of Atherosclerosis and Thrombosis·Xue-Mei HeXiang-Yu Zhou
Aug 30, 2017·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Shui-Chuan HuangShen-Ming Wang

❮ Previous
Next ❯

Citations

Nov 18, 2020·Molecules and Cells·Woo Ryung KimHeui-Soo Kim
Sep 17, 2021·Angiologii︠a︡ i sosudistai︠a︡ khirurgii︠a︡ = Angiology and vascular surgery·R A KalininA A Egorov
Nov 4, 2020·Current Pharmaceutical Design·Stavroula A PaschouDimitrios Tousoulis

❮ Previous
Next ❯

Methods Mentioned

BETA
amputation
Protein Assay
electrophoresis
transfection
Assay
dissecting
flow cytometry

Software Mentioned

- Pad Prism
SPSS
Image
Graph
Pro Plus

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.